Reimbursement & Market Access
It has become more apparent that regulatory success does not automatically equate to commercial success.
EXCLUSIVE CONTENT:
Download our analysis of the
cost effectiveness studies
for the Top 20 Highest
Selling Drugs
-------------------------
Access the Archived
Webinar on
Comparative Effectiveness
Product Development:
With R & MA in mind
with Chuck Stevens
Case Study |
| A Complete Review of Reimbursement Status |
| Learn More > |
The New "Make or Break" of Product Success
It has become apparent that regulatory success does not automatically equate to commercial success. Companies want to develop products with a competitive advantage when compared to competing products and alternative treatments. Doing so will allow access to the greatest potential population of users.
Developing with reimbursement and market access (RMA) in mind has become the new "make or break" of product commercial success. By understanding "market access" implications during development companies can design the right trial, create an optimal label, better leverage "evidence-based" or "outcome-based" medicine, and eliminate "access hurdles" by demonstrating patient, payer and provider value. Your company can also align clinical investment to payer reimbursement and patient access trends.
PAREXEL Consulting is uniquely positioned in its approach, fusion of expertise and integrated services to support product commercial success.
Clinical Trial Protocol Integration
- Optimal Clinical Trial Design
- Development of an Optimal Label
- Comparative Effectiveness Research (Phase III/IIIb/IV)
- Analysis of Clinical Endpoints
- Quality of Life (QoL) and Patient Reported Outcomes (PRO)
Market Analysis and Access Assessment
- Competitive Product Reimbursement Analysis
- Payer Coverage Analysis
- Health Policy Review and Implications to Commercialization
- Setting of Care Considerations and Associated Payment Values
- Review of Patient Access Hurdles
- Product Coding Requirements and Strategy Development (HCPCS/CPT)
- Compendia Coverage Analysis and Submissions
Economic Modeling
- Cost Effectiveness
- Cost Utility
- Budget Impact
- Quality Added Life Year (QALY)
Economic and Clinical Value Messaging
- Local and Global Value Dossier Preparation and Submission
- Local Dossier Translations: EU and AMCP (US)
- Pricing and Reimbursement Committee Negotiations
Payer Strategy and Communications
- Virtual Health Economies
- Payer Advisory Boards
- Mock P & T Committees
- Journal Publications
- Congress and Symposia Presentations and Posters
HelpLine™ Contact Centers
- Reimbursement
- Patient Assistance Program (PAP)
- Risk Evaluation and Mitigation Strategy (REMS)
- Product Information
Value Proposition:
Thinking beyond regulatory approval, and addressing reimbursement and market access, allows an increased opportunity for payer acceptance and revenue by leveraging "evidence-based" or "outcome-based" medicine. That means utilizing trial design and clinical data to provide clear product differentiation resulting in optimal payer reimbursement that achieves business objectives.
An innovative market access approach also allows for an improved understanding of health policy and payer coverage trends to drive market launch strategies (e.g. selected points of strong coverage).
The downside of not addressing reimbursement and market access early in product development is the potential failure to demonstrate product value and results in more restrictive patient access hurdles being imposed by payers. Furthermore, matching client regulatory and clinical investment to payer reimbursement and patient access trends maximizes ROI throughout development.
Contact Us:
For further information and to get in touch with our experts, please use our contact us form and type "R&MA" in the comment field or contact Nathan.White@parexel.com. Thank you!
